World Health Organization (2019) Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 15 Sept 2023

World Health Organization (2019) Obesity. https://www.who.int/health-topics/obesity#tab=tab_1. Accessed 15 Sept 2023

Abed HS, Wittert GA (2013) Obesity and atrial fibrillation. Obes Rev 14(11):929–938. https://doi.org/10.1111/obr.12056

Article  PubMed  CAS  Google Scholar 

Frost L, Hune LJ, Vestergaard P (2005) Overweight and obesity as risk factors for atrial fibrillation or flutter: the danish diet, cancer, and health study. Am J Med 118(5):489–495. https://doi.org/10.1016/j.amjmed.2005.01.031

Article  PubMed  Google Scholar 

Stein PD, Beemath A, Olson RE (2005) Obesity as a risk factor in venous thromboembolism. Am J Med 118(9):978–980. https://doi.org/10.1016/j.amjmed.2005.03.012

Article  PubMed  Google Scholar 

Altiok E, Marx N (2018) Oral anticoagulation. Dtsch Arztebl Int 115(46):776–783. https://doi.org/10.3238/arztebl.2018.0776

Article  PubMed  PubMed Central  Google Scholar 

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, Group ESCSD (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612

Article  PubMed  Google Scholar 

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL, Group ESCSD (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405

Article  PubMed  Google Scholar 

Drug Discovery & Development (2023) The 50 best-selling pharmaceuticals of 2022. https://www.drugdiscoverytrends.com/50-of-2022s-best-selling-pharmaceuticals/. Accessed 1 Oct 2023

Reilly PA et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in Atrial Fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol 63(4):321–328

Article  PubMed  CAS  Google Scholar 

Cohen D (2014) Dabigatran: how the drug company withheld important analyses. BMJ 349:g4670

Article  PubMed  Google Scholar 

Ruff CT et al (2015) Association between edoxaban dose, concentration, anti-factor xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385(9984):2288–2295

Article  PubMed  CAS  Google Scholar 

FDA. Center for drug evaluation and research. Application number: 202155Orig1s000. Medical review (s). Apixaban clinical review addendum. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155orig1s000medr.pdf. Accessed 11 Dec 2023

Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 14(6):1308–1313. https://doi.org/10.1111/jth.13323

Article  PubMed  PubMed Central  CAS  Google Scholar 

Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2021) Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation. J Thromb Haemost 19(8):1874–1882. https://doi.org/10.1111/jth.15358

Article  PubMed  Google Scholar 

Summary of product characteristics Eliquis (apixaban). Bristol-Myers Squibb/Pfizer. European medicines agency. https://www.ema.europa.eu/. Accessed 1 Sept 2023

Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, Committee AS, Investigators (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806–817. https://doi.org/10.1056/NEJMoa1007432

Article  PubMed  CAS  Google Scholar 

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, Investigators A-E (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368(8):699–708. https://doi.org/10.1056/NEJMoa1207541

Article  PubMed  CAS  Google Scholar 

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, Investigators A (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808. https://doi.org/10.1056/NEJMoa1302507

Article  PubMed  CAS  Google Scholar 

Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, Investigators A (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487–2498. https://doi.org/10.1056/NEJMoa1006885

Article  PubMed  CAS  Google Scholar 

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, Investigators A (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717):807–815. https://doi.org/10.1016/S0140-6736(09)62125-5

Article  PubMed  CAS  Google Scholar 

Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez LM, Ramacciotti E, Lassen MR, Wang L (2013) Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost 11(3):444–451. https://doi.org/10.1111/jth.12109

Article  PubMed  CAS  Google Scholar 

Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD (2019) Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation 139(20):2292–2300. https://doi.org/10.1161/CIRCULATIONAHA.118.037955

Article  PubMed  CAS  Google Scholar 

Stockley’s Drug Interaction Checker. Pharmaceutical press. Medicines complete. https://www.medicinescomplete.com/#/interactions/stockley

Janusmed Interaction Database. Region Stockholm. https://janusmed.se/interaktioner

Bottiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjo ML, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B (2009) SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 65(6):627–633. https://doi.org/10.1007/s00228-008-0612-5

Article  PubMed  Google Scholar 

Bjork J, Grubb A, Sterner G, Nyman U (2011) Revised equations for estimating glomerular filtration rate based on the lund-malmo study cohort. Scand J Clin Lab Invest 71(3):232–239. https://doi.org/10.3109/00365513.2011.557086

Article  PubMed  Google Scholar 

DuBois D (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Medicine 17:863–871. https://doi.org/10.1001/archinte.1916.00080130010002

Article  CAS  Google Scholar 

Devine BJ (1974) Gentamicin therapy. Drug Intell Clin Pharm 8:650–655

Google Scholar 

Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Ronquist-Nii Y, Soderblom L, Ostlund AY, Pohanka A, Antovic J, Malmstrom RE (2015) Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res 136(1):148–153. https://doi.org/10.1016/j.thromres.2015.04.030

Article  PubMed  CAS  Google Scholar 

Martin AC, Thomas W, Mahir Z, Crowley MP, Dowling T, Breen K, Collings V, Moore GW, MacDonald S, Hunt BJ, Cohen AT (2021) Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study. Thromb Haemost 121(2):224–233. https://doi.org/10.1055/s-0040-1715834

Article  PubMed  Google Scholar 

Russo V, Cattaneo D, Giannetti L, Bottino R, Laezza N, Atripaldi U, Clementi E (2021) Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. Clin Ther 43(9):e255–e263. https://doi.org/10.1016/j.clinthera.2021.07.003

Article  PubMed  CAS  Google Scholar 

Piran S, Traquair H, Chan N, Bhagirath V, Schulman S (2018) Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. Res Pract Thromb Haemost 2(4):684–688. https://doi.org/10.1002/rth2.12146

Article